A prospective open trial of guanfacine in children with pervasive developmental disorders.

OBJECTIVE A common complaint for children with pervasive developmental disorder (PDD) is hyperactivity. The purpose of this pilot study was to gather preliminary information on the efficacy of guanfacine in children with PDD and hyperactivity. METHODS Children with PDD accompanied by hyperactivity entered the open-label trial if there was a recent history of failed treatment with methylphenidate or the child did not improve on methylphenidate in a multisite, placebo-controlled trial. RESULTS Children (23 boys and 2 girls) with a mean age of 9.03 (+/-3.14) years entered the open-label trial. After 8 weeks of treatment, the parent-rated Hyperactivity subscale of the Aberrant Behavior Checklist (ABC) went from a mean of 31.3 (+/-8.89) at baseline to 18.9 (+/-10.37) (effect size = 1.4; p < 0.001). The teacher-rated Hyperactivity subscale decreased from a mean of 29.9 (+/-9.12) at baseline to 22.3 (+/-9.44) (effect size = 0.83; p < 0.01). Twelve children (48%) were rated as Much Improved or Very Much Improved on the Clinical Global Impressions- Improvement. Doses ranged from 1.0 to 3.0 mg/day in two or three divided doses. Common adverse effects included irritability, sedation, sleep disturbance (insomnia or midsleep awakening), and constipation. Irritability led to discontinuation in 3 subjects. There were no significant changes in pulse, blood pressure, or electrocardiogram. CONCLUSIONS Guanfacine may be useful for the treatment of hyperactivity in children with PDD. Placebo-controlled studies are needed to guide clinical practice.

[1]  Luc Lecavalier,et al.  Behavioral and Emotional Problems in Young People with Pervasive Developmental Disorders: Relative Prevalence, Effects of Subject Characteristics, and Empirical Classification , 2006, Journal of autism and developmental disorders.

[2]  C. McDougle,et al.  Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. , 2005, Archives of general psychiatry.

[3]  A. Arnsten,et al.  Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions , 2004, Biological Psychiatry.

[4]  C. McDougle,et al.  Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. , 2004, Journal of child and adolescent psychopharmacology.

[5]  L. E. Arnold,et al.  Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies. , 2003, Journal of child and adolescent psychopharmacology.

[6]  S. West,et al.  Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study , 2002 .

[7]  H. Singer,et al.  Neuropsychiatric Effects of Guanfacine in Children With Mild Tourette Syndrome: A Pilot Study , 2002, Clinical neuropharmacology.

[8]  C. McDougle,et al.  Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.

[9]  S. Havercamp,et al.  Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education. , 2002, Research in developmental disabilities.

[10]  J. Biederman,et al.  Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial , 2001, European Neuropsychopharmacology.

[11]  R. Schultz,et al.  A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. , 2001, The American journal of psychiatry.

[12]  E. Fombonne,et al.  Pervasive developmental disorders in preschool children. , 2001, JAMA.

[13]  Elizabeth B. Owens,et al.  Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[14]  H. Kraemer,et al.  Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[15]  Colin Studholme,et al.  The Alpha-2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow in Dorsolateral Prefrontal Cortex of Monkeys Performing a Spatial Working Memory Task , 2000, Neuropsychopharmacology.

[16]  A. Rush,et al.  Expert Consensus Guideline Series: Treatment of psychiatric and behavioral problems in mental retardation. , 2000, American journal of mental retardation : AJMR.

[17]  Stephen P. Hinshaw,et al.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. , 1999, Archives of general psychiatry.

[18]  S. Bradley-Johnson.  Mullen Scales of Early Learning , 1997 .

[19]  J. Bregman,et al.  Diagnosing Autism: Analyses of Data from the Autism Diagnostic Interview , 1997, Journal of Autism and Developmental Disorders.

[20]  B. Leventhal,et al.  Clonidine Treatment of Hyperactive and Impulsive Children with Autistic Disorder , 1992, Journal of clinical psychopharmacology.

[21]  M. Aman,et al.  Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation , 1992, Journal of autism and developmental disorders.

[22]  M. Aman,et al.  The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. , 1985, American journal of mental deficiency.